Canada Markets close in 5 hrs 9 mins

Satsuma Pharmaceuticals, Inc. (STSA)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
23.51-0.49 (-2.02%)
As of 10:50AM EDT. Market open.

Satsuma Pharmaceuticals, Inc.

400 Oyster Point Boulevard
Suite 221
South San Francisco 94080
United States
650 410 3200
http://www.satsumarx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Mr. John A. KollinsPres, CEO & Director558.59kN/A1963
Mr. Thomas P. O'NeilChief Financial Officer475.18kN/A1965
Dr. Detlef F. AlbrechtChief Medical Officer483.2kN/A1961
Mr. Mic IwashimaVP & Head of OperationsN/AN/A1978
Mr. Robert SchultzVP & Head of CMCN/AN/A1964
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

Corporate Governance

Satsuma Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.